Iopofosine I-131's accelerated approval path in post-BTKi WM hinges on FDA accepting Phase 2b data as registrational and runway surviving confirmatory Phase 3 enrollment

Bull

A complete and accepted EMA CMA submission based on the 61.8% MRR, 83.6% ORR, and 17.8-month median DoR from CLOVER-WaM would confirm that a major regulatory agency views the Phase 2b dataset as registration-quality, substantially de-risking the parallel FDA accelerated approval pathway and providing a credible commercial revenue bridge while the confirmatory Phase 3 enrolls. A clean filing acceptance would also validate the post-BTKi refractory WM label scope, positioning iopofosine I-131 as the first approved radiopharmaceutical in this orphan population and anchoring a premium pricing argument in Europe.

Bear

The EMA could issue a Day 120 list of outstanding issues questioning the single-arm Phase 2b design, the response assessment methodology, or the adequacy of safety follow-up data given the small protocol population (n=55), potentially requiring additional data packages that extend the timeline and strain the milestone-gated financing structure. A refusal to validate the CMA pathway or a request for randomized data before conditional approval would undermine the entire regulatory strategy and signal that FDA accelerated approval faces analogous evidentiary challenges, compressing the runway before the Phase 3 generates confirmatory evidence.